 |
Indication & Dosage |
| |
| |
| Subcutaneous |
| PROPHYLAXIS OF VENOUS THROMBOEMBOLISM DURING MODERATE-RISK SURGICAL PROCEDURES |
| Adult:
1750 anti-XaIU, given 2 hr prior to surgery. Continue once daily dosing until patient is fully mobile. |
| |
| Subcutaneous |
| PROPHYLAXIS OF VENOUS THROMBOEMBOLISM DURING HIGH-RISK SURGICAL PROCEDURES |
| Adult:
4200 anti-XaIU, given 12 hr before surgery. Continue once daily dosing until patient is fully mobile and for at least 14 days. |
| |
| Subcutaneous |
| TREATMENT OF THROMBOEMBOLISM |
| Adult:
Initiate treatment upon confirmation of diagnosis. 35-45 kg: 3500 anti-XaIU; 46-60 kg: 4200 anti-XaIU and >60 kg: 6300 anti-XaIU. Doses to be given bid with an oral anticoagulant. Usual treatment duration with reviparin: 5-7 days. |
|
| |
|
| Precautions |
Elderly (women in particular); lactation; children; renal failure; diabetes mellitus. Platelet count done before and during reviparin therapy. Monitor anti-factor-Xa activity in patients with increased risk of bleeding such as elderly, renally impaired patients and patients with active bleeding. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Vomiting, constipation, epistaxis, conjunctivitis, asthma, rhinitis. Bleeding from skin, mucosa, GI tract, wounds and genital tract; thrombosis; thromboembolism; consumption coagulopathy; Inj site necrosis; melena; petechiae; purpura; allergic features like pruritus, urticaria; nausea, headache, fever, body pain, dyspnoea and hypotension; transient alopoecia, hyperkalaemia, hypoaldosteronism; metabolic acidosis; priapism. |
| |
|
| Adverse Drug Reactions |
Severe thrombocytopaenia with severe thromboembolic disorders and haemorrhage. |
| |
|
| Interactions |
Nitroglycerin infusion may diminish reviparin effect. May displace propranolol from protein-binding sites. Increased risk of haemorrhage when used with aspirin. Increased risk of hyperkalaemia when used with ACE inhibitors or angiotensin II receptor antagonists. |
| |
|
|
|
